TECFIDERA
PeakNDAORALCAPSULE, DELAYED RELEASE
Approved
Mar 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECFIDERA (dimethyl fumarate) is an oral, delayed-release small molecule immunomodulator approved in 2013 for relapsing-remitting multiple sclerosis (RRMS). It reduces disease activity and slows disability progression in MS patients by modulating immune cell function. The drug is currently in peak commercial performance with strong market penetration.
$0.235BPart D
PeakStable
9.0 years to LOETECFIDERA remains a revenue-generating peak franchise with significant commercial infrastructure; expect stable team size focused on market defense and patient retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
Started Jun 2024
10,500 enrolled
Multiple Sclerosis
Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)
Started Mar 2023
11 enrolled
Multiple Sclerosis (MS) Relapsing Remitting
Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera
Started Mar 2021
1,507 enrolled
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP
Started Aug 2019
353 enrolled
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
Started Mar 2019
11 enrolled
Multiple Sclerosis, Relapsing-Remitting
Worked on TECFIDERA at Biogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.